Can branded GLP-1 medicines replace compounded weight-loss drugs in Hims & Hers growth strategy?
Lilly is bringing Zepbound and Foundayo to Hims & Hers, turning a former GLP-1 disruptor into a branded obesity-drug distribution channel.
Features & Analysis
Medical Devices & Diagnostics
Novo Nordisk buys Ginkgo Bioworks’ autonomous lab. Can robotics rescue its shrinking revenue?
Ginkgo Bioworks sells its first pharma autonomous lab to Novo Nordisk as Q3 losses narrow. Examine revenue, cash burn and execution.
Pharma & Biotech
Eli Lilly brings Zepbound and Foundayo to Hims & Hers, but who gains most from the deal?
Eli Lilly and Hims & Hers expand access to Zepbound and Foundayo from $149 monthly. Discover the impact on obesity medicine distribution.
Pharma & Biotech
Orbis names a new CEO after its $1.4bn billion Novo Nordisk deal, but can AI-designed macrocycles replace injections?
Orbis names Joanne Smith-Farrell CEO after its $1.4 billion Novo Nordisk partnership. The next test is advancing AI-designed oral macrocycles.
Pharma & Biotech
Novo Nordisk bets up to $2.6bn on Hengrui’s once-weekly oral GLP-1/GIP drug
Novo Nordisk licenses Hengrui’s once-weekly oral GLP-1/GIP candidate HRS-1596 in a deal worth up to $2.6 billion.
Pharma & Biotech
Eli Lilly just cut basal insulin dosing from 365 injections to 52. Can Onswik catch Novo Nordisk’s Awiqli?
Eli Lilly and Company has secured U.S. Food and Drug Administration approval for Onswik, its once-weekly basal insulin for adults with type 2 diabetes, bringing a second weekly insulin into the U.S. market and shifting the competitive question from regulatory feasibility to prescribing, access and real-world adoption.
Pharma & Biotech
Viking Therapeutics stock drops after hours as $400m raise follows 36% VK2735 surge
Viking Therapeutics is seeking $400 million through stock and convertible-note offerings immediately after VK2735 obesity data sent its shares sharply higher, as the company accelerates Phase 3 development and explores monthly and every-other-week maintenance dosing.
Pharma & Biotech
Novo Nordisk’s Sogroya moves closer to becoming EU’s first approved treatment for idiopathic short stature
European regulators have backed once-weekly Sogroya for children with idiopathic short stature, potentially giving Novo Nordisk the first EU-approved growth hormone specifically for the condition while expanding a rare-endocrine franchise beyond growth hormone deficiency.
Pharma & Biotech
Novo Nordisk brings Anthropic’s Claude into drug discovery as AI partnerships move deeper into pharmaceutical R&D
Novo Nordisk has expanded its artificial-intelligence strategy through a collaboration with Anthropic that will test Claude Science in pharmaceutical R&D, adding another AI partner as the drugmaker seeks faster research productivity amid intensifying competitive pressure.
Pharma & Biotech
Can low doses of Ozempic, Wegovy, Mounjaro and Zepbound still cause weight loss?
A new real-world study of sustained low-dose semaglutide and tirzepatide found measurable weight loss without escalation to standard maintenance doses, but researchers stress that prescription records do not prove intentional GLP-1 microdosing and the observational findings cannot establish cause and effect.